

Screening
Up to 5 weeks
Lead-in Period
Treatment Period
Double Blind 6 Weeks
Withdrawal Period
MDD patients with MADRS Total 25
n = 324
Placebo
n = 181
Responders
n = 45
Non Responders
n = 124
Adjunctive Placebo
Adjunctive Aticaprant 10 mg
Adjunctive Placebo
Adjunctive Aticaprant 10 mg
Primary Analysis - eITT
Placebo
n = 181
Week 0
Week 11
Screening
Lean-in Baseline
Treatment Baseline
Treatment Endpoint
Placebo Responder
Placebo Non-Responder

FIG. 1



35.0
30.0
25.0
20.0
15.0
10.0
5.0
Mean ± SE
Lead-in Baseline
Lead-in Wk 1
Lead-in Wk 2
Lead-in Wk 3
Trt Wk 1
Trt Wk 3
Trt Wk 4
Trt Wk 5
Trt Wk 6
Withdrawl Wk 2
Visit
Number of Subjects
Placebo 61 61 59 61 61 59 60 60 59 59
JNJ-67953964 10mg 60 60 58 59 60 59 57 55 59 58
Placebo
JNJ-67953964 10mg

FIG. 2

Population	Treatment	LsMean Diff. (SE) JNJ - Placebo	60% CI JNJ - Placebo	p-value
Enriched	JNJ-67953964 10mg	-2.14 (1.252)	[-3.20, -1.09]	0.0443
Full	JNJ-67953964 10mg	-3.09 (1.049)	[-3.97, -2.21]	0.0017





FIG. 3



Number of Subjects					
Placebo	61	59	60	60	59
JNJ-67953964 10mg	60	59	57	56	59

FIG. 4



Population Treatment
LsMean Diff. (SE) JNJ - Placebo
80% CI JNJ - Placebo
p-value
Enriched JNJ-67953964 10mg
-0.70 (0.865)
[-1.81, 0.41]
0.4188
Full JNJ-67953964 10mg
-0.85 (0.735)
[-1.79, 0.10]
0.2503
←Favours Active
Favours Placebo→
-4 -3 -2 -1 0 1 2 3 4

FIG. 5



Mean ± SE
35.0
30.0
25.0
20.0
15.0
10.0
5.0
Lead-in Baseline
Lead-in Wk 1
Lead-in Wk 2
Lead-in Wk 3
Trt Wk 1
Trt Wk 3
Trt Wk 4
Trt Wk 5
Trt Wk 6
Withdrawl Wk 2
Visit
Number of Subjects
Placebo 61 61 59 61 61 59 60 60 59 59
JNJ-67953964 10mg 60 60 58 59 60 59 57 55 59 58
Placebo
JNJ-67953964 10mg

FIG. 6



35.0
30.0
25.0
20.0
15.0
10.0
5.0
Mean ± SE
Lead-in Baseline
Lead-in Wk 1
Lead-in Wk 2
Lead-in Wk 3
Trt Wk 1
Trt Wk 3
Trt Wk 4
Trt Wk 5
Trt Wk 6
Withdrawl Wk 2
Visit
Number of Subjects
Placebo 83 82 81 83 83 81 82 82 81 81
JNJ-67953964 10mg 83 83 80 82 83 80 78 76 77 79
Placebo
JNJ-67953964 10mg

FIG. 7A



GREATER IMPROVEMENT
LSMean Change (+/- SE)
0
-1
-2
-3
-4
-5
-6
-7
-8
-9
-10
-11
-12
^ = p value < 0.05 based on 1-sided test
* All patients continued their baseline SSRI/SNRI during the DB phase
Placebo + Oral Antidepressant*
Aticaprant + Oral Antidepressant*
0
1
3
4
5
6
Time (weeks)

FIG. 7B



40
35
30
25
20
15
10
5
0
% Patients
Trt Wk 1
Trt Wk 3
Trt Wk 4
Trt Wk 5
Trt Wk 6
Visit
Number of Subjects
Placebo 61 59 60 60 59
JNJ-67953964 10mg 60 59 57 55 59
Placebo
JNJ-67953964 10mg

FIG. 8



40
35
30
25
20
15
10
5
0
% Patients
Trt Wk 1
Trt Wk 3
Trt Wk 4
Trt Wk 5
Trt Wk 6
Visit
Number of Subjects
Placebo 83 81 82 82 81
JNJ-67953964 10mg 83 80 78 76 77
Placebo
JNJ-67953964 10mg

FIG. 9



70
60
50
40
30
20
10
0
% Patients
Trt Wk 1
Trt Wk 3
Trt Wk 4
Trt Wk 5
Trt Wk 6
Visit
Number of Subjects
Placebo 61 59 60 60 59
JNJ-67953964 10mg 60 59 57 55 59
Placebo
JNJ-67953964 10mg

FIG. 10



70
60
50
40
30
20
10
0
% Patients
Trt Wk 1
Trt Wk 3
Trt Wk 4
Trt Wk 5
Trt Wk 6
Visit
Number of Subjects
Placebo 83 81 82 82 81
JNJ-67953964 10mg 82 79 77 75 76
Placebo
JNJ-67953964 10mg

FIG. 11



70
60
50
40
30
20
10
0
% Patients
Trt Wk 1
Trt Wk 3
Trt Wk 4
Trt Wk 5
Trt Wk 6
Visit
Number of Subjects
Placebo 61 59 60 60 59
JNJ-67953964 10mg 60 59 57 55 59
Placebo
JNJ-67953964 10mg

FIG. 12



70
60
50
40
30
20
10
0
% Patients
Trt Wk 1
Trt Wk 3
Trt Wk 4
Trt Wk 5
Trt Wk 6
Visit
Number of Subjects
Placebo 83 81 82 82 81
JNJ-67953964 10mg 82 79 77 75 76
Placebo
JNJ-67953964 10mg

FIG. 13



Mean ± SE
40.0
39.0
38.0
37.0
36.0
35.0
34.0
33.0
32.0
31.0
30.0
29.0
Lead-in Baseline
Lead-in Wk 1
Lead-in Wk 2
Lead-in Wk 3
Trt Wk 1
Trt Wk 3
Trt Wk 4
Trt Wk 5
Trt Wk 6
Withdrawl Wk 2
Visit
Number of Subjects
Placebo 61 61 59 61 61 59 60 60 59 59
JNJ-67953964 10mg 60 60 58 59 60 59 57 56 59 58
Placebo
JNJ-67953964 10mg

FIG. 14




Mean ± SE
40.0
39.0
38.0
37.0
36.0
35.0
34.0
33.0
32.0
31.0
30.0
29.0
Lead-in Baseline
Lead-in Wk 1
Lead-in Wk 2
Lead-in Wk 3
Trt Wk 1
Trt Wk 3
Trt Wk 4
Trt Wk 5
Trt Wk 6
Withdrawl Wk 2
Visit
Number of Subjects
Placebo 82 82 81 83 83 81 82 82 81 81
JNJ-67953964 10mg 83 83 80 82 83 80 78 77 77 79
Placebo
JNJ-67953964 10mg

FIG. 15



LSMD (60% CI)	Aticaprant (n)	Placebo (n)	Effect Size
-3.15 (-4.04, -2.26)	76	81	0.38
-3.16 (-4.05, -2.27)	75	81	0.38
-3.17 (-4.07, -2.27)	75	81	0.38
-3.30 (-4.19, -2.40)	75	80	0.40
-3.47 (-4.40, -2.55)	71	79	0.41
-3.47 (-4.44, -2.50)	62	74	0.42
-3.43 (-4.48, -2.39)	58	66	0.40
-3.56 (-4.71, -2.42)	49	60	0.41
-3.74 (-5.07, -2.41)	41	47	0.41
-4.94 (-6.55, -3.33)	29	34	0.55
-5.53 (-7.88, -3.19)	18	20	0.6

Effect size is based on LS Mean Difference and Pooled SD

FIG. 16




FIG. 17A




FIG. 17B




FIG. 18



GREATER IMPROVEMENT
Mean Change ASEX Total Score (SE)
1
0
-1
-2
0
1
2
3
4
5
6
Time (weeks)
Placebo +
Oral Antidepressant*
Aticaprant +
Oral Antidepressant*

FIG. 19



Item 1
Sexual Drive
Item 2
Sexual arousal
Item 3
Vaginal lubrication/
Erection
Item 4
Reach orgasm
Item 5
Orgasms satisfying
Greater Improvement
-0.5
-0.4
-0.3
-0.2
-0.1
0
Mean Change at Week 6
Aticaprant
Placebo

FIG. 20



Screening Phase
4 weeks
Double-Blind Treatment Phase
6 weeks
End of Study
Open Label or Follow-up Phase
Primary Analysis
ANH +
Aticaprant 10 mg*
n = 157
Placebo*
n = 157
MDD patients with insufficient response to SSRI/SNRI
ANH -
Aticaprant 10 mg*
n = 98
Placebo*
n = 98
Non-completers
Follow-Up Phase
2 weeks
Completers
Open Label Extension Study
52 weeks

FIG. 21



Screening Phase
4 weeks
Double-Blind Treatment Phase
8 weeks
End of Study
Open Label or Follow-up Phase
Aticaprant 5 mg*
n = 139
Aticaprant 10 mg*
n = 139
Placebo*
n = 278
MDD patients with insufficient response to SSRI/SNRI
Non-completers
Follow-Up Phase
2 weeks
Completers
Open Label Extension Study
52 weeks

FIG. 22



SHAPS<38
SHAPS>=38
Enjoy Beautiful Landscape/View
Enjoy Being With Family/Friends
Enjoy Favorite Meal
Enjoy Favorite TV/Radio Program
Enjoy Looking Smart
Enjoy Reading
Enjoy Smiling Faces
Enjoy Tea, Coffee, Favorite Drink
Enjoy Warm Bath/Refreshing Shower
Feel Pleasure Receiving Praise
Find Pleasure in Hobbies/Pastimes
Find Pleasure in Scents/Smells
Find Pleasure in Small Things
Get Pleasure from Helping Others
-0.6
-0.4
-0.2
0.0
LS Means at Week 6
Placebo (N=81)
JNJ-67953964 10mg (N=77)

FIG. 23



Diff of LS Means (60% CI)
Placebo (N)
JNJ-67953964 (N)
Age Group
18-44 Years -2.70 (-3.90,-1.51) 43 44
45-64 Years -3.65 (-4.98,-2.33) 38 33
Gender
Female -2.61 (-3.66,-1.57) 60 54
Male -3.97 (-5.67,-2.28) 21 23
MADRS at Treatment Baseline
< Median (26.5) -1.26 (-2.52,0.01) 42 34
>= Median (26.5) -4.76 (-6.01,-3.51) 39 43
SHAPS at Treatment Baseline
<38 -1.87 (-3.00,-0.73) 47 48
>=38 -5.07 (-6.58,-3.55) 34 29
CPFQ at Treatment Baseline
< Median (26) -4.36 (-5.66,-3.06) 40 33
>= Median (26) -2.02 (-3.23,-0.80) 41 44
SATE at Treatment Baseline
Improved -0.98 (-2.33,0.37) 34 26
Not Changed/Worsened -4.93 (-6.14,-3.73) 38 42
SIGH-A at Treatment Baseline
<=24 -2.76 (-3.70,-1.82) 72 66
>24 -5.74 (-8.41,-3.08) 9 9
SMDDS at Treatment Baseline
< Median (29) -2.45 (-3.84,-1.06) 33 32
>= Median (29) -3.53 (-4.70,-2.36) 48 45
Benzodiazepine Use in Trt Phase
Yes -6.14 (-9.28,-3.00) 9 5
No -2.87 (-3.80,-1.94) 72 72
AD Class for the Current Episode of Depression
SSRI -4.05 (-5.05,-3.05) 63 61
SNRI -0.36 (-2.32,1.59) 16 16
Duration of AD that is Continued into Trt Phase
<= 18 Weeks -3.59 (-4.92,-2.25) 31 38
>18 Weeks -1.97 (-3.33,-0.61) 38 28
Duration of Current Episode
<= 24 Weeks -3.42 (-4.61,-2.23) 46 42
>24 Weeks -2.65 (-4.01,-1.30) 35 35
Single vs Recurrent MDD
Single Mdd -5.25 (-6.96,-3.54) 24 16
Recurrent MDD -2.52 (-3.55,-1.50) 57 59
Number of Episodes of MDD
1 -5.26 (-6.94,-3.57) 24 18
2 -0.33 (-2.65,1.99) 11 12
>=3 -3.08 (-4.21,-1.95) 46 47
Country
Germany 0.87 (-2.91,4.66) 4 5
Great Britain -0.84 (-3.21,1.53) 10 12
Moldovia -4.66 (-6.79,-2.53) 14 14
Russia -3.63 (-5.31,-1.95) 24 21
USA -3.32 (-5.10,-1.55) 21 19
Ukraine -4.48 (-7.53,-1.44) 8 6
-14 -12 -10 -8 -6 -4 -2 0 2 4 6 8 10 12 14
Favors JNJ-67953964
Favors Placebo

FIG. 24